Featured Jobs
|
Retirement Relationship Manager MAP Retirement
|
|
Defined Benefit Plan Consultant/Actuarial Analyst Sentinel Group
|
|
Pattison Pension
|
|
MAP Retirement
|
|
DWC - The 401(k) Experts
|
|
Strategic Retirement Plan Consultant Retirement Plan Consultants
|
|
Plan Administrator, Defined Benefit & Cash Balance The Pension Source
|
|
Sentinel Group
|
|
Regional Vice President, Sales MAP Retirement
|
|
BPAS
|
|
MAP Retirement
|
Free Newsletters
“BenefitsLink continues to be the most valuable resource we have at the firm.”
-- An attorney subscriber
|
|
|
Assessing Drug Price Increases in Medicare Part D and the Implications of Inflation Limits
Henry J. Kaiser Family Foundation 
Oct. 21, 2019 "Among the top 25 drugs by total Medicare Part D spending in 2017, all of which were brand-name drugs, 20 had list price increases between 2016 and 2017 that exceeded the inflation rate, in some cases by several percentage points ... Among the 96 drugs used by more than 1 million Part D enrollees in 2017, roughly one-fifth of these drugs (22 drugs) had list price increases between 2016 and 2017 above the rate of inflation." MORE >> |
| Please click here to report this link if it is broken (for example, if you see a "404 File Not Found" error message after you click on the linked news item's title). |
| An important word about authorship: BenefitsLink® created this link to the news item, but we are not the news item's author (unless expressly shown above). |